Abnormal Histone Acetylation and Methylation Levels in Esophageal Squamous Cell Carcinomas

REFERENCES

• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24(14):2137–2150.
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349(23):2241–2252.
   PubMed Web of Science ®Google Scholar
• Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97(2):142–146.
   PubMed Web of Science ®Google Scholar
• Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001;234(3):360–367; discussion 368–369.
   PubMed Web of Science ®Google Scholar
• Morita M, Kuwano H, Ohno S, Sugimachi K, Seo Y, Tomoda H, Furusawa M, Nakashima T. Multiple occurrence of carcinoma in the upper aerodigestive tract associated with esophageal cancer: reference to smoking, drinking and family history. Int J Cancer 1994;58(2):207–210.
   PubMed Web of Science ®Google Scholar
• Tomizawa Y, Wang KK. Screening, surveillance, and prevention for esophageal cancer. Gastroenterol Clin North Am 2009;38(1):59–73, viii.
   PubMed Web of Science ®Google Scholar
• Paliwal A, Vaissiere T, Krais A, Cuenin C, Cros MP, Zaridze D, Moukeria A, Boffetta P, Hainaut P, Brennan P, Herceg Z. Aberrant DNA methylation links cancer susceptibility locus 15q25.1 to apoptotic regulation and lung cancer. Cancer Res 2010;70(7):2779–2788.
   PubMed Web of Science ®Google Scholar
• Kreisler A, Strissel PL, Strick R, Neumann SB, Schumacher U, Becker CM. Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer. Oncogene 2010;29(43):5828–5838.
   PubMed Web of Science ®Google Scholar
• Vasavi M, Ponnala S, Gujjari K, Boddu P, Bharatula RS, Prasad R, Ahuja YR, Hasan Q. DNA methylation in esophageal diseases including cancer: special reference to hMLH1 gene promoter status. Tumori 2006;92(2):155–162.
   PubMed Web of Science ®Google Scholar
• Long C, Yin B, Lu Q, Zhou X, Hu J, Yang Y, Yu F, Yuan Y. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma. Cancer Invest 2007;25(8):685–690.
   PubMed Web of Science ®Google Scholar
• Chen C, Yin B, Wei Q, Li D, Hu J, Yu F, Lu Q. Aberrant DNA methylation in thymic epithelial tumors. Cancer Invest 2009;27(5):582–591.
   PubMed Web of Science ®Google Scholar
• Kulis M, Esteller M. DNA methylation and cancer. Adv Genet 2010;70:27–56.
   PubMed Web of Science ®Google Scholar
• Vialou V. Histone acetylation, gene regulation and depression. Med Sci (Paris) 2010;26(5):465–467.
   PubMed Web of Science ®Google Scholar
• Schubeler D, Lorincz MC, Cimbora DM, Telling A, Feng YQ, Bouhassira EE, Groudine M. Genomic targeting of methylated DNA: influence of methylation on transcription, replication, chromatin structure, and histone acetylation. Mol Cell Biol 2000;20(24):9103–9112.
   PubMed Web of Science ®Google Scholar
• Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol 2004;14(14):R546–R551.
   PubMed Web of Science ®Google Scholar
• Plath K, Fang J, Mlynarczyk-Evans SK, Cao R, Worringer KA, Wang H, de la Cruz CC, Otte AP, Panning B, Zhang Y. Role of histone H3 lysine 27 methylation in X inactivation. Science 2003;300(5616):131–135.
   PubMed Web of Science ®Google Scholar
• Toh Y, Yamamoto M, Endo K, Ikeda Y, Baba H, Kohnoe S, Yonemasu H, Hachitanda Y, Okamura T, Sugimachi K. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep 2003;10(2):333–338.
   PubMed Web of Science ®Google Scholar
• Thompson SK, Ruszkiewicz AR, Jamieson GG, Esterman A, Watson DI, Wijnhoven BP, Lamb PJ, Devitt PG. Improving the accuracy of TNM staging in esophageal cancer: a pathological review of resected specimens. Ann Surg Oncol 2008;15(12):3447–3458.
   PubMed Web of Science ®Google Scholar
• Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007;8(4):286–298.
   PubMed Web of Science ®Google Scholar
• Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435(7046):1262–1266.
   PubMed Web of Science ®Google Scholar
• Barlesi F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, Lefesvre P, Kruyt FA, Rodriguez JA. Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 2007;25(28):4358–4364.
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia E, Licht JD. Deregulation of H3K27 methylation in cancer. Nat Genet 2010;42(2):100–101.
   PubMed Web of Science ®Google Scholar
• Hansen KH, Bracken AP, Pasini D, Dietrich N, Gehani SS, Monrad A, Rappsilber J, Lerdrup M, Helin K. A model for transmission of the H3K27me3 epigenetic mark. Nat Cell Biol 2008;10(11):1291–1300.
   PubMed Web of Science ®Google Scholar
• Cao R, Wang H, He J, Erdjument-Bromage H, Tempst P, Zhang Y. Role of hPHF1 in H3K27 methylation and Hox gene silencing. Mol Cell Biol 2008;28(5):1862–1872.
   PubMed Web of Science ®Google Scholar
• He LR, Liu MZ, Li BK, Rao HL, Liao YJ, Guan XY, Zeng YX, Xie D. Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer 2009;9:461.
   PubMed Web of Science ®Google Scholar
• Chen H, Gu X, Su IH, Bottino R, Contreras JL, Tarakhovsky A, Kim SK. Polycomb protein Ezh2 regulates pancreatic beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus. Genes Dev 2009;23(8):975–985.
   PubMed Web of Science ®Google Scholar
• Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008;647(1–2):21–29.
   PubMed Web of Science ®Google Scholar
• Tzao C, Tung HJ, Jin JS, Sun GH, Hsu HS, Chen BH, Yu CP, Lee SC. Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod Pathol 2009;22(2):252–260.
   PubMed Web of Science ®Google Scholar
• Lee MG, Norman J, Shilatifard A, Shiekhattar R. Physical and functional association of a trimethyl H3K4 demethylase and Ring6a/MBLR, a polycomb-like protein. Cell 2007;128(5):877–887.
   PubMed Web of Science ®Google Scholar
• Yamane K, Tateishi K, Klose RJ, Fang J, Fabrizio LA, Erdjument-Bromage H, Taylor-Papadimitriou J, Tempst P, Zhang Y. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell 2007;25(6):801–812.
   PubMed Web of Science ®Google Scholar
• Magerl C, Ellinger J, Braunschweig T, Kremmer E, Koch LK, Holler T, Buttner R, Luscher B, Gutgemann I. H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. Hum Pathol 2010;41(2):181–189.
   PubMed Web of Science ®Google Scholar
• Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004;119(7):941–953.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W, Liang J, Sun L, Yang X, Shi L, Li R, Li Y, Zhang Y, Li Q, Yi X, Shang Y. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009;138(4):660–672.
   PubMed Web of Science ®Google Scholar
• Tzao C, Sun GH, Tung HJ, Hsu HS, Hsu WH, Wang YC, Cheng YL, Lee SC. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma. Ann Thorac Surg 2006;82(2):396–401; discussion 401.
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6(1):38–51.
   PubMed Web of Science ®Google Scholar
• Park JH, Jung Y, Kim TY, Kim SG, Jong HS, Lee JW, Kim DK, Lee JS, Kim NK, Bang YJ. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 2004;10(15):5271–5281.
   PubMed Web of Science ®Google Scholar
• Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY, Nam SW. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005;113(4):264–268.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004;46(2):171–178.
   PubMed Web of Science ®Google Scholar
• Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, Wang Z, Osman I, Lee P. Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 2009;1(1):62–71.
   PubMedGoogle Scholar
• Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics 2008;3(1):28–37.
   PubMed Web of Science ®Google Scholar
• Fan J, Yin WJ, Lu JS, Wang L, Wu J, Wu FY, Di GH, Shen ZZ, Shao ZM. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol 2008; 134(8):883–890.
   PubMed Web of Science ®Google Scholar
• Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP, Sinclair DA. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008;3(4):e2020.
   PubMed Web of Science ®Google Scholar
• Vinciguerra M, Santini MP, Claycomb WC, Ladurner AG, Rosenthal N. Local IGF-1 isoform protects cardiomyocytes from hypertrophic and oxidative stresses via SirT1 activity. Aging (Albany NY) 2010;2(1):43–62.
   Google Scholar
• Yi J, Luo J. SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta 2010;1804(8):1684–1689.
   PubMed Web of Science ®Google Scholar
• Stimson L, La Thangue NB. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 2009;280(2):177–183.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang Y, Pang X. Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression. Med Oncol 2010; Epub ahead of print. ]
   Web of Science ®Google Scholar
• Murakami K, Matsubara H, Hoshino I, Akutsu Y, Miyazawa Y, Matsushita K, Sakata H, Nishimori T, Usui A, Kano M, Nishino N, Yoshida M. CHAP31 induces apoptosis only via the intrinsic pathway in human esophageal cancer cells. Oncology 2010;78(1):62–74.
   PubMed Web of Science ®Google Scholar